Cosibelimab induces encouraging response rate in cSCC, justifying BLA submission to FDA
Early results from an international phase 1 study of cosibelimab are encouraging and could lead to the submission of a biologics license application to the FDA.Cosibelimab Treatment Achieved a Promising Objective Response Rate (ORR) in…